The difference between satelizumab (Anshiping) and inelizumab

Satralizumab (Satralizumab) and inebilizumab are both drugs used to treat neuromyelitis optica (NMOSD), but they are different in terms of pharmacological mechanisms, administration methods, research data and safety. The choice of drug should be decided by the doctor based on the patient's specific situation.

1. Pharmacological mechanism: Satclizumab is a soluble humanized monoclonal antibody that blocks IL-6 signaling by binding to the IL-6 receptor. Inelizumab is a monoclonal antibody that targets CD19-expressing B cells and reduces the onset of NMOSD by targeting and eliminating these B cells.

2. Medication: Satelizumab needs to be injected subcutaneously every 4 weeks. Inelizumab is administered as an intravenous injection every 6 months.

3. Research data: Both drugs have undergone clinical trials and have shown significant efficacy. However, their research data are slightly different due to differences in the time between drug development and clinical use. The specific choice of drug should take into account the patient's condition, tolerance, and doctor's recommendations.

4. Safety: Common side effects of both drugs include infection, headache, injection site reaction, etc. Specific safety and risk of side effects may also vary, so it's best to discuss and evaluate them with your doctor before use.

The original drug satlizumab has been launched in China, sold under the brand name Anshiping, and is included in medical insurance. Only patients who meet the indications can be reimbursed. The specification is120mg (1ml) per box The price may be more than RMB 10,000, which is still relatively expensive; the price of each box of the original drug Saterizumab sold overseas is more than $10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.